Business Context and Reporting Period
This Form 8-K is filed by AcelRx Pharmaceuticals, Inc. (ACRX) on April 30, 2020. The filing primarily updates investors on the proposed merger with Tetraphase Pharmaceuticals, Inc. (Tetraphase), originally announced on March 15, 2020. The filing incorporates by reference the audited financial statements of Tetraphase and unaudited pro forma combined financial information from the effective Form S-4 registration statement. Additionally, the company provides preliminary estimated operating results for the quarter ended March 31, 2020.
Key Financial Metrics
The filing provides preliminary estimates for AcelRx's quarter ended March 31, 2020, noting that the financial close process was not yet complete and figures are unaudited.
- Cash Position: Estimated cash, cash equivalents, and short-term investments of $52.7 million as of March 31, 2020.
- Revenue: Estimated total revenues of $0.4 million for the quarter ended March 31, 2020.
- Operating Expenses: Estimated combined SG&A and R&D expenses of $14.7 million for the quarter ended March 31, 2020.
- Profitability: Based on the estimates provided, the company incurred a significant operating loss for the quarter.
- Debt and Liquidity: Specific debt figures are not provided in this text; liquidity is indicated by the $52.7 million cash estimate.
Material Changes and M&A Activity
The most significant material change is the progression of the merger with Tetraphase. The Form S-4 registration statement was declared effective by the SEC on April 24, 2020, and the definitive proxy statement/prospectus was mailed to Tetraphase stockholders on or about April 28, 2020. The filing includes unaudited pro forma condensed combined financial information reflecting the merger as if it had occurred on December 31, 2019 (balance sheet) and January 1, 2019 (statement of operations).
Outlook, Risks, and Management Commentary
Management emphasizes that the financial estimates for the quarter ended March 31, 2020, are preliminary and subject to change upon completion of financial closing procedures. The independent registered public accounting firm has not audited these estimates.
Key Risks and Contingencies:
- Merger Completion: Risk that the acquisition of Tetraphase may not close or that expected benefits and cost synergies may not be achieved.
- Financial Accuracy: Potential changes in the estimated cash position following final audit and closing procedures.
- Market Conditions: Potential sales volumes to the Department of Defense may not materialize.
- Pandemic Impact: Risks related to the ongoing COVID-19 pandemic, which may be prolonged or exacerbated.
Investor Verification Checklist
- Verify the final audited financial results for the quarter ended March 31, 2020, once the financial close is complete, as current figures are estimates.
- Review the definitive proxy statement/prospectus (Form S-4) for detailed pro forma financial data and merger terms.
- Monitor the status of the Tetraphase merger vote and closing conditions.
- Assess the impact of the COVID-19 pandemic on the company's cash burn rate and Department of Defense sales pipeline.
- Confirm the final cash position after the independent auditor reviews the March 31, 2020, financial statements.